Drug Trial Radar · NCT07128394
Extra Luteinizing Hormone Improve Embryo Quality in IVF Patients With Low LH During Long GnRH-Agonist Treatment
Last checked: Nov 20, 2026Latest source record: Aug 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
590
Planned (sponsor's estimate)
Start
Feb 1, 2024
Primary completion
Sep 30, 2026
Study completion Nov 30, 2026
Sponsor
- Lead sponsor
- Nanjing UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 19, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 20 years, up to 37 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized controlled trial aims to evaluate whether supplementation with exogenous luteinizing hormone (LH) can improve embryo quality in patients undergoing in vitro fertilization (IVF) with a long gonadotropin-releasing hormone agonist (GnRH-a) protocol who have excessive suppression of LH. Eligible participants will be randomly assigned to receive either exogenous LH supplementation or standard care. The primary outcome is embryo quality, and secondary outcomes include pregnancy rates and safety assessments. The study is conducted at Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University.
Conditions
- Infertility, Female
- Luteinizing Hormone (LH)
Interventions
Recombinant Luteinizing Hormone (rLH)Drug
Recombinant LH administered subcutaneously in combination with recombinant FSH (rFSH) at a ratio of 2:1 starting on stimulation day, continued throughout controlled ovarian hyperstimulation. Dosage adjusted according to follicular growth and serum hormone levels.
Recombinant Follicle-Stimulating Hormone (rFSH)Drug
Recombinant FSH administered subcutaneously for controlled ovarian hyperstimulation after pituitary downregulation with a long-acting GnRH agonist. Dosage adjusted based on follicular development and hormone monitoring.
Gonadotropin-Releasing Hormone Agonist (GnRH-a)Drug
Long-acting GnRH agonist (3.75 mg) administered subcutaneously on menstrual cycle day 2-4 for pituitary downregulation before controlled ovarian hyperstimulation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of cycles with no usable embryosTime frame: 7 days after oocyte retrieval
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nanjing Drum Tower Hospital, Nanjing University Medical School
Nanjing, Jiangsu, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.